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~56”’ is a T cell-specific protein tyrosine kinase of the src family of proto-oncogenes which has been implicated in T cell signal transduction. Here 
we describe the production of mouse monoclonal antibodies directed against recombinant human ~56”~ purified from an E. colr expression system. 
The antibodies were characterized by ELISA, RIA and immunoprecipitation of ~56’~~ from T cell lysates. A specific epitope was revealed at the 
aminoterminus of the ~56”’ molecule by using Western blotting of deletion mutants and distinct domains of ~56”’ expressed in E. coli. Potential 
apphcations of the results obtained are discussed. 
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1. INTRODUCTION 
Growth regulation, proliferation and differentiation 
of cells are controlled by extracellular signals that ulti- 
mately lead to alterations in gene expression. Protein 
tyrosine kinases are crucially involved in these proc- 
esses. They are subdivided into two groups: cell surface 
receptor protein tyrosine kinases and non-receptor pro- 
tein tyrosine kinases. Particular attention was drawn to 
the src family of proto-oncogenes, cytoplasmic, non- 
receptor protein tyrosine kinases which have been 
found associated with several cell surface receptors [l- 
51. They are key elements of many signal transduction 
pathways transducing the signals received at cell surface 
receptors to the cell interior [6]. 
The protein tyrosine kinase ~56”” is a typical member 
of the src family of protein tyrosine kinases expressed 
at high levels in T lymphocytes [7]. In vivo ~56”~ is 
myristoylated at the aminoterminal glycine residue 
[8,9]. This modification directs ~56”~ to the cytoplasmic 
face of the cell membrane, where it has been demon- 
strated to be physically associated with CD4 and CD8 
cell surface receptors [3-51. The individual kinases are 
quite conserved among species and there is a high se- 
quence identity among the various family members. The 
homology of ~56”~ to ~60’~“” is especially high within 
the kinase domain. The homologies within the src ho- 
mology regions 2 and 3 (SH2 and SH3) are lower but 
still significant. Targeted mutation of the Ick locus by 
homologous recombination in mice showed severe defi- 
Correspondence address M. Stieger, F. Hoffmann-La Roche Ltd., 
Pharmaceutical Research-New Technologies, CH-4002 Basel, Swit- 
zerland. Fax: (41) (61) 688 4575. 
ciencies of the immune system [lo]. These and other 
findings indicate that ~56”~ is of crucial importance in 
the activation of mature T lymphocytes and the selec- 
tion of maturing T cells in the thymus. 
The catalytic activity of ~56”” is regulated through 
phosphorylation/dephosphorylation of the tyrosine res- 
idue at position 505 by phosphotyrosine phosphatase 
CD45 [2,11,12] and the protein tyrosine kinase ~50’““ 
[13-161. Excessive or deregulated activity of p56’ck leads 
to malignant transformation [17,18]. ~56”~ has also 
been shown to modulate the activities of several pro- 
teins involved in signal transduction pathways [19], in- 
cluding rasGAP [20], MAPK [21], PI-3-kinase [22], 
and Vav [23]. 
In this paper we report the production and character- 
ization of mouse monoclonal antibodies (mAb’s) di- 
rected against human recombinant ~56”~ purified from 
an E. coli expression system. In order to determine the 
epitopes recognized by the individual mAb’s several dif- 
ferent deletion mutants and single domains of ~56”” 
were constructed, expressed in E. coli. and probed in 
Western blotting experiments together with the mAb’s. 
2. MATERIALS AND METHODS 
2.1. Immunization and production of mouse monoclonal antibodzes 
Human ~56”’ was overexpressed in E co11 using pDS expression 
vectors [24] and purified to homogeneity. Female Balb/Cj mice (6 
weeks old) were tmmumzed with 20 pg of purified ~56”’ emulsified in 
1 vol. of complete Freund’s adjuvant (Difco). The antigen dose was 
given partly subcutaneously (s.c., 4 x 50 ~1) and partly intrapentone- 
ously (i.p., 100 ~1). The immumzation was repeated i.p. with the same 
dose/mouse m incomplete Freund’s adjuvant at 30 day intervals. Small 
amounts of blood were taken from the tail vem 14 days after the boosts 
and tested for antibody titer by Enzyme-linked immunosorbant assays 
or radio-immunoassays (ELISA or RIA, see below). After reachmg 
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high enough serum titers the mice were boosted once more i.p. wlthout 
adjuvant and sacrificed 4 days later. The spleen was aseptically re- 
moved, teased and a monocellular suspension of splenocytes was fused 
with the PAI myeloma cell line [25]. Hybrldoma cell populations were 
grown in selective media and their supernatants were examined for 
specificity by ELISA. The best reactmg hybrldomas were recloned and 
expanded. The mAb’s they produced were further analyzed for lsotype 
and speclfty usmg Western blotting techniques. Five such mAb’s were 
selected, produced in large quantities and purified on protein-A col- 
umns. The purdied mAb’s were all of the IgG2a subclass and were 
designated as 8F12-G8. 2C12-C7. 2Cl2-E9. 6C1-Bll and lD5-Cl. 
2.2. ELISAIRIA 
Microtiter plates were coated with purified ~56”’ at 2 pg/ml in PBS. 
To reduce unspecific bmdmg the plates were then saturated with 1% 
BSA followed by overnight incubation with 100 yl of hybrldoma 
supernatant or diluted serum. Reacted antibodies were revealed with 
phosphatase-linked or peroxldase-linked anti-mouse IgG followed by 
the appropriate substrate. Alternatively “51-labelled arm-mouse IgG 
antibodies were also used as detectmg agents. 
2.3. Plasmid constructrons 
All Ick-encodmg sequences were derived from the plasmid pUCl?/ 
YTl6 [26]. pUC12/YTl6 was digested with NcoI. the resulting 5’ 
overhang was filled m followed by digestion with HlndIII. The result- 
ing 1,837 bp fragment was ligated into the plasmld pDS56RBSII(-1) 
[24] which had been cut with Hind11 and HilzdIII. The resulting plas- 
mid encodes the protem MRDPS-~56”“. All different variants ofpS6”” 
were cloned by PCR. The plasmid encoding MRDPS-P~~“~ was used 
as a template in PCR reactions using the primers shown m Table I. 
The PCR fragments encoding amino-terminal deletion mutants of 
p56”” were digested with NcoI and HuzdIll and cloned into 
pDS56RBSILNcoI [34] which had been digested with NcuI and 
HmdIII. The PCR-fragments encodmg the SH3+SH2. the SH3 and 
the SH2 domain were dlgested with Bur?lHI and cloned into the 
BanlHI site of the vector pDS56RBSII(-2) [WI. 
All expresslon plasmids were transformed into the E coil stram 
Ml5 [27] containmg the repressor plasmld pREP4 [24]. Smgle colonies 
were picked and the presence of k&-encoding sequences was verified 
by restriction enzyme digestlon of mm]-prep DNA. Colonies that 
contamed I&-encoding plasmids were cultured in LB medmm to an 
optlcal density of 0.6 and the expression of the recombinant p56”“- 
variants was then induced by addition of IPTG to 2 mM. After 4 h 
of mductlon the E cob cells were pelleted by centnfugatlon and the 
pellet was dissolved m sample buffer. 
2.4. Protem electrophores~s und Western hlottmg 
Proteins were separated by reducing SDS gel electrophoresis on 
12.5%(w/v) polyacrylamlde gels [28]. The gels were either stamed with 
Coomassle blue or electrophoretically transferred onto mtrocellulose 
membranes. The mtrocellulose membranes were then probed with 
mouse monoclonal antlbodies or with rabbit polyclonal antiserum 
specific for ~56”“. After washmg. the membranes were reacted with 
peroxidase-labelled goat anti-mouse or goat anti-rabbit antibodles. 
The signal was developed by using the ECL-system (Amersham) as 
described by the manufacturer 
2.5. Immunoprecip~tatron and krnase cr~says 
Immunoprecipitallons and in vitro kinase assays were performed as 
described by Amrem et al. [20]. 
3. RESULTS 
We have raised mouse mAb’s specific for the protein 
tyrosine kinase ~56”~ by following the immunization 
and selection procedures described in Material and 
Methods. Five mAb’s were chosen and further analyzed 
in immunoprecipitation experiments. Detergent lysates 
42 
1 2 3 
30kd 
Fig. 1. Immunoprecipitation of ~56”’ from T cell lysates and in vitro 
kinase assays (Autoradiogrdmm). Lane 1 1 preimmuneserum; lane 2. 
polyclonal rabbit anti-p56”” antiserum: lane 3. mAb X12-C7: lane 4, 
mAb lD5-Cl; lane 5. mAb 6Cl-Bll: lane 6, mAb SFll-G8. 
of T lymphocytes were probed with the mAb’s and im- 
munecomplexes formed were subjected to in vitro ki- 
nase reaction experiments. Results show that all five 
mAb’s specifically precipitate a phosphoprotein of the 
apparent M, of 56 kDa (Fig. 1, and data not shown). 
Rabbit polyclonal antibodies revealed the same protein 
whereas pre-immune sera did not precipitate any detect- 
able phosphoprotein (Fig. 1). Thus, we conclude that 
each of the five mAb’s tested specifically recognizes and 
immunoprecipltates ~56”“. 
To determine the epitope recognized by the individual 
mAb’s several variants of ~56”” (Fig. 2) were produced 
in E. coli. The expression of the ~56”” variants was 
demonstrated by SDS-polyacrylamide gel electrophore- 
sis of E. coli cell extracts followed by Coomassie blue 
staining of the gels. All variants of ~56”‘~. except 
MRDPS_p56”“, p56”k-“-‘o and the SH2 domain of 
~56”~, gave a visible band (Fig. 3). 
Table I 
Primers used in PCR reactlons 
IeLf l-9 
/chll-30 
l&Al-48 
l&Al -60 
I&-kinase 
domain 
[ck-SH3+SH’ 
domain 
Irk-SH3 
domain 
lck-SH3 
domain 
S’agctcaccca~ggaagatgac3 
j’gggcctctcaagctttcctctcaa3’ 
S’atagtccccatggatggcaag3’ 
S’gggcctctcaagctttcctctcaa3’ 
5’cgggaccccatggttacctac3’ 
S’gggcctctcaagctttcctctcaa3’ 
S’gcttcccccatggaagacaac3’ 
S’gggcctctcaagctttcctctcaa3’ 
5’ccagaagcccatggagccgtgg3’ 
S’gggcctctcaagctttcctctcaa3’ 
S’ccggatcccactgcaagacaacctggttat3’ 
5’taggatccgggcttctgggtctggcagg3’ 
S’ccggatcccactgcaagacaacctggttat3’ 
5’tag~gatccgggttcgggctccaggctgttc3’ 
S’ccggatcccctggttcttcaagaacctgagcc3’ 
5’tdggatccgggcttctggtctggcagg3’ 
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SH3 SHZ Kfnase doman 
r/j\ p5Glck 
IchAi -9 
IchAl-30 
ICkAl-48 
IckAl -GO 
K~nasc domajn 
SH3+SHE domatn 
SH3 domaln 
SHZ doma,” 
Fig. 2. Schematic structure of ~56” and its variants. 
Western blotting experiments using polyclonal rabbit 
anti-p561ck antisera confirmed that all variants of ~56”’ 
were expressed in E. coli, although at different levels 
(Fig. 4a). In these experiments the SH2 and SH3 do- 
mains were detectable only after prolonged exposure of 
the blots (data not shown). 
To identify the epitope(s) recognized by the five dif- 
ferent mAb’s directed against ~56”” Western blotting 
experiments were performed. Four out of the five 
mAb’s tested reacted with MRDPS-P~~“~ but neither of 
them recognized any of the amino-terminal ~56”~ dele- 
tion mutants, nor did they react with any of the isolated 
domains of ~56”~ (Fig. 4b). Fig. 4b shows the im- 
munoblot obtained using the mAb 8F12-G8. The same 
results were obtained using the mAb 6C 1 -B 11,2C 12-E9 
and lD5-Gl, whereas the mAb 2C12-C7 did not react 
92kd 
66kd 
43kd 
31kd 
21kd 
14kd 
Ml23456789 
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Fig. 3. Over-expression of ~56” variants in E. coli 12% (w/v) SDS- 
polyacrylamide gel stained with Coomassie blue. Lane 1, MRDPS- 
~56”‘; lane 2, ~56”~‘~~: lane3, ~56”~~‘-~“; lane4, ~56”“~‘~‘: lane 5. 
~56”~*‘-“; lane 6, p56”‘-kinase domain: lane 7, ~56”“-SH3+SH2 do- 
main; lane 8, ~56’“~SH3 domain; lane 9. p56”‘-SH2 domain. 
12 3 4 5 6 7 8 
a) 
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Fig. 4. Immunoblot with (a) rabbit polyclonal anti-p56”’ antisera, and 
(b) mouse mAb 8Fl2G8. Lane 1, MRDPS-P~~“~; lane 2, p56’ck“‘-‘0; 
lane 3, p56 ,&r+; Lane 4, p56”~d”bo; lane 5. p56”k-kinase domain; lane 
6, p56”‘-SH3+SH2 domam; lane 7, ~56”~-SH3 domain; lane 8, ~56”~- 
SH2 domain. 
with any of the ~56”~ variants tested in these experi- 
ments. These results demonstrate that an amino-termi- 
nal deletion of 30 amino acids of ~56”~ is sufficient to 
destroy the epitope recognised by four different rnAb’s. 
Moreover, additional studies using the amino-terminal 
deletion mutant ~56”‘~‘-~ demonstrated that the epitope 
recognized by the four mAb’s lies within the very 
amino-terminus of ~56”~ (data not shown). 
To verify that the first few amino-terminal amino 
acids of ~56”~ constitute an epitope recognized by the 
mAb’s, MRDPS-P~~“~ was blotted onto nitrocellulose 
and Western blotting experiments were performed in 
the presence or absence of two synthetic peptides corre- 
sponding to amino acids 1-14 (peptide no. 11’861-B6) 
and 617 (peptide no. 11’861-BlO) of ~56”~. Both pep- 
tides completely blocked the recognition of MRDPS- 
~56”~ by mAb 8F12-G8 if present in a l,OOO-fold excess 
over ~56”~ (Fig. 5). The peptide corresponding to amino 
acids l-14 of ~56“~ blocked the reaction of MRDPS- 
~56“~ with the mAb partially even if present in equal 
amounts (Fig. 5a). 
43 
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lck 
II861-BG=Ac-GCGCSSHPEDDWWE-NH2 
I I 86 I-B IO=Ac-SSHPEDDWMENID-NH2 
Fig, 5 Immunoblot with mouse mAb 8F12-G8 in the absence (-) or 
presence of 100 ng or 100 pg of the two pepttdes: (a) pepttde no 
11’681-B6 (amino acids I- 14) and (b) pepttde no 11’861-810 (ammo 
actds6617). 100 ng of purified MRDPS-~56”” were spotted m each 
case. 
4. DISCUSSION 
In this study we have described the production and 
characterization of five mouse mAb’s raised against the 
human protein tyrosine kinase ~56”“. Four of the 
mAb’s map to the extreme amino-terminus of p56”l’ and 
thus reveal a common and specific epitope on ~56~“. 
The fifth monoclonal antibody (Xl 2-C7) seems to rec- 
ognize a conformational epitope since it does not react 
with ~56”’ in Western blotting experiments. but is able 
to immunoprecipitate ~56”’ from T cell lysates. The 
finding of a specific recognition of an epitope displayed 
at the amino-terminus of ~56“” by our mAb’s is not 
unique since mouse mAb’s raised in an other laboratory 
are also preferentially directed to the amino-terminus of 
~56”” (personal communication). 
The fact that our mAb’s react only with the amino- 
terminus of p56/‘” could indicate that lymphocyte clones 
recognizing other sequences of ~56”” are eliminated 
during thymic selection. Indeed mouse p56/” is highly 
homologous to human ~56”’ (96.3% overall homology) 
__I 
whereas within the amino-terminus the homology is 
lower (80% homology in the first 10 amino-terminal 
amino acids). This lower homology of the amino-termi- 
nal ~56”~ sequences might allow a preferential selection 
of T cell clones recognizing such an epitope. 
In a recent publication Rouer and Benarous reported 
the discovery of a splice variant of ~56”” in which the 
first 35 amino-terminal amino acids of ~56”” are re- 
placed by 10 residues starting at an alternative AUG 
start codon [19]. The mAb’s described in this publica- 
tion could be used to discriminate between the two vari- 
ants of ~56”~ and therefore might provide an ideal tool 
to study the expression and tissue distribution pattern 
of the ~56”“ variants. Moreover, they could be used in 
a variety of biochemical as well as cell biological studies, 
in vitro and in vivo. to analyze the properties and func- 
tions of the two splice forms. 
In a series of additional experiments we have used the 
peptide corresponding to the epitope recognized by the 
mAb’s to elute ~56”” from a mAb-immunoaffinity col- 
umn (data not shown). Results indicate that, using this 
peptide, ~56”’ can be eluted specifically from the col- 
umn m a biologically active form. This will allow the 
affinity purification of ~56”~ under mild conditions, 
thereby avoiding the harsh treatments that are normally 
used to disrupt antigen-antibody interactions. 
Another application might be to use the epitope se- 
quence recognized in this paper as a tag for other pro- 
teins. By DNA cloning the epitope sequence could be 
linked to any recombinant protein in such a way that 
it can serve both as a signal for myristoylation and as 
a tag for the detection and the purification of the recom- 
binant protein. This combination of epitope tag, mono- 
clonal antibody and synthetic peptide, thus offers the 
possibility of purifying recombinant proteins under 
conditions expected to maintain full biological activity. 
Moreover. any tagged protein could easily be visualized 
in intact cells using the mAb’s in immunofluorescence 
studies. 
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